Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 5063 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
REVIEW ARTICLE
Year : 2013  |  Volume : 17  |  Issue : 5  |  Page : 835-843

Importance of achieving the composite endpoints in diabetes


1 Department of Clinical Endocrinology, Chellaram Diabetes Institute, Budruk, Pune, Maharashtra, India
2 Department of Endocrinology, Manipal Hospital, Bangalore, India
3 Excel Centre, Guwahati, India
4 Department of Diabetes and Endocrinology, AMRI Hospital, Kolkata, India
5 MS Ramaiah Medical College, Bangalore, India
6 Nizam's Institute of Medical Sciences, Hyderabad, India

Correspondence Address:
Ambika Gopalakrishnan Unnikrishnan
Department of Clinical Endocrinology, Chellaram Diabetes Institute, 1st Floor, Lalani Quantum, Pune-Bangalore Highway, Bavdhan Budruk, Pune - 411 021, Maharashtra
India
Login to access the Email id

Source of Support: Writing Support by Novo Nordisk, Conflict of Interest: None


DOI: 10.4103/2230-8210.117225

Rights and Permissions

Well-conducted randomized controlled trials are instrumental in providing vital data on safety and efficacy of new molecules under consideration for approval. However acquiring such data involves huge cost and focused scientific endeavor. Selection and reporting of endpoints of a therapy is essential to assess the effect(s) of an intervention on overall disease control and guidelines have suggested the use of composite endpoint (CEP) in clinical trial design over individual endpoints to demonstrate the compound effect. Composite endpoints have been preferred for their ability to assess the net clinical benefit of an intervention, avoid misinterpretation associated with competing risks, avoid the challenge of using a single outcome to validate the study objectives and reduce the sample size requirements in trials on patients treated for diabetes. Concerns for misinterpretation or difficulty in interpretation of trial results involving CEPs arise when differences in the components with respect to either clinical importance or event rates, or magnitude of treatment effect exist and when there's a possibility of biases due to competing risk. Suggestions for construction of composite endpoints and reporting the results of trials involving CEPs have been presented to improve the interpretations of overall effect of new interventions.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1757    
    Printed14    
    Emailed0    
    PDF Downloaded310    
    Comments [Add]    
    Cited by others 4    

Recommend this journal